Key result
Achieved in-treatment systolic blood pressure ≤130 mm Hg was associated with a 40% lower risk of new-onset atrial fibrillation compared with ≥142 mm Hg (HR 0.60; 95% CI 0.45-0.82).
Why the study?
Does achieving a lower on-treatment systolic blood pressure reduce the risk of new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy?
RCT (n=8,831)
randomly assigned
Does achieving a lower on-treatment systolic blood pressure reduce the risk of new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy?
Hazard Ratio: 0.6 (95% CI 0.45–0.82)
Achieving a lower on-treatment systolic blood pressure (≤141 mm Hg) is associated with a significantly reduced risk of incident atrial fibrillation in high-risk hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Targeting SBP ≤130 mm Hg may reduce new-onset AF; extends BP-lowering RCT data to arrhythmia prevention.
Okin et al. (2015) conducted an RCT in Hypertension with ECG left ventricular hypertrophy (n=8,831). In-treatment SBP ≤130 mm Hg vs. In-treatment SBP ≥142 mm Hg was evaluated on New-onset atrial fibrillation (HR 0.60, 95% CI 0.45-0.82). Achieved in-treatment systolic blood pressure ≤130 mm Hg was associated with a 40% lower risk of new-onset atrial fibrillation compared with ≥142 mm Hg (HR 0.60; 95% CI 0.45-0.82).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: